Cardiol Therapeutics Inc. (CRDL)
Automate Your Wheel Strategy on CRDL
With Tiblio's Option Bot, you can configure your own wheel strategy including CRDL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CRDL
- Rev/Share 0.0
- Book/Share 0.1429
- PB 11.4537
- Debt/Equity 0.0121
- CurrentRatio 2.4647
- ROIC -2.5309
- MktCap 137004914.633
- FreeCF/Share -0.3037
- PFCF -5.4586
- PE -3.6018
- Debt/Assets 0.0071
- DivYield 0
- ROE -2.3266
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CRDL | H.C. Wainwright | -- | Buy | -- | $9 | June 2, 2025 |
| Initiation | CRDL | Rodman & Renshaw | -- | Buy | -- | $7 | Jan. 28, 2025 |
News
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027
Published: October 21, 2025 by: Newsfile Corp
Sentiment: Neutral
MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA. New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through to heart failure, to be presented at a cardiology conference in November 2025.
Read More
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.
Read More
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference
Published: August 11, 2025 by: Newsfile Corp
Sentiment: Neutral
Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will participate in a Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference in Boston, MA, on August 12, 2025, at 9:30 a.m. EDT. A live webcast of the Fireside Chat will be accessible under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/).
Read More
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors
Published: April 29, 2025 by: Newsfile Corp
Sentiment: Neutral
Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experience Toronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that pharmaceutical industry veteran Timothy J. Garnett, M.D.
Read More
About Cardiol Therapeutics Inc. (CRDL)
- IPO Date 2019-01-15
- Website https://www.cardiolrx.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO David G. Elsley MBA
- Employees 18